Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Economic burden of relapse/recurrence in patients with major depressive disorder

Open access
Gauthier, Genevieve, Mucha, Lisa, Shi, Sherry, Guerin, Annie · 2019 · Journal of Drug Assessment

Abstract

Objective: This study was conducted to determine the incremental healthcare resource utilization (HRU) and costs associated with relapse or recurrence (R/R) in patients with major depressive disorder (MDD) treated with antidepressants (AD) in US clinical practice.Methods: In this retrospective cohort study, adult patients with MDD treated with a branded AD were selected from the Truven Health Analytics MarketScan Databases (January 1, 2004–March 31, 2015). Time to first indicator of R/R was described. Characteristics, HRU, and costs were compared between patients with and without R/R. Among patients with R/R, HRU and costs were also compared between the pre- and post-R/R period.Results: From the 22,236 selected patients, 5,541 had ≥ 1 indicator of R/R and 16,695 did not. The 3-year R/R rate varied between 21.3% and 36.4% based on pattern of AD use (continuous, switch/augmentation, or early discontinuation). Patients with and without R/R presented different characteristics—notably, more intensive prior AD use and a higher comorbidity burden. HRU and costs were high in both patients with and without R/R but substantially higher among those with R/R ($20,590 vs $12,368 per-patient-per-year (PPPY); adjusted difference [aDiff] = $7,037), mainly driven by increased inpatient (IP) services (adjusted incidence rate ratio IP days = 3.95; aDiff IP costs = $3,433 PPPY). Among patients with R/R, emergency department visits, IP days, and IP admissions were over 2-times higher during the post-R/R period and total costs increased by over 50% from $19,267 to $29,419 in the post-R/R period.Conclusions: The economic burden in MDD patients is substantial, but is significantly higher among those who experience R/R.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21556660.2019.1612410

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Time to first indicator of R/R. R/R, relapse or recurrence.
Figure 1. Time to first indicator of R/R. R/R, relapse or recurrence.CC BY-NC · PubMed Central
Figure 2. Average all-cause healthcare costs PPPY: patients with relapse/recurrence vs patients without relapse/recurrence. Models were controlled for the following baseline characteristics: age, sex, region of residence, type of healthcare plan, Charlson Comorbidity Index score, and whether or not patients used atypical antipsychotics, typical antipsychotics, and anxiolytics. aDiff, adjusted difference. ED, emergency department; IP, inpatient; OP, outpatient; PPPY, per-patient-per-year. *p < 0.05.
Figure 2. Average all-cause healthcare costs PPPY: patients with relapse/recurrence vs patients without relapse/recurrence. Models were controlled for the following baseline characteristics: age, sex, region of residence, type of healthcare plan, Charlson Comorbidity Index score, and whether or not patients used atypical antipsychotics, typical antipsychotics, and anxiolytics. aDiff, adjusted difference. ED, emergency department; IP, inpatient; OP, outpatient; PPPY, per-patient-per-year. *p < 0.05.CC BY-NC · PubMed Central
Figure 3. Average all-cause healthcare costs PPPY: pre-relapse/recurrence vs post-relapse/recurrence period. ED, emergency department; IP, inpatient; OP, outpatient; PPPY, per-patient-per-year. *p < 0.05.
Figure 3. Average all-cause healthcare costs PPPY: pre-relapse/recurrence vs post-relapse/recurrence period. ED, emergency department; IP, inpatient; OP, outpatient; PPPY, per-patient-per-year. *p < 0.05.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 3

  1. Armstrong C, 2011, Am Fam Physician, 83, 1219
  2. Thaipisuttikul P, 2014, Neuropsychiatr Dis Treat, 10, 2097
  3. Sood N, 2000, Am J Manag Care, 6, 1327

Cited by

See all 36

Metadata

Authors
Gauthier, G., Mucha, L., Shi, S., & Guerin, A.
Affiliations
  • Analysis Group, Inc, Montreal, Canada;
  • Takeda (United States) (US)
Venue
Journal of Drug Assessment
Published
2019-01-01
Volume
8
Issue
1
Pages
97-103
ISSN
  • 1369-9474 (ISSN-L)
  • 2155-6660
OpenAlex
W2942805562
Cited by
36
References
23
Citations by year
2026: 5 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 2
FWCI
2.79
Type
journal article
Language
en
Open access
Locations
  • Journal of Drug Assessment (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Takeda Pharmaceutical Center USA
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
major depressive disorder, relapse and recurrence, antidepressants, healthcare resource utilization, health care costs, inpatient services, emergency department visits, antidepressant discontinuation, comorbidities, economic burden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic burden of relapse/recurrence in patients with major depressive disorder. https://app.cochat.ai/papers/10.1080/21556660.2019.1612410
The paper
Gauthier, G., Mucha, L., Shi, S., & Guerin, A. (2019). Economic burden of relapse/recurrence in patients with major depressive disorder. Journal of Drug Assessment. https://doi.org/10.1080/21556660.2019.1612410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.